Arsenic trioxide (As2O3) inhibits expression of estrogen receptor-alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cells

Reproductive Sciences

Volumn 15, Issue 10, 2008, Pages 1011-1017

  Bae Jump, Victoria L ^a   Chunxiao Zhou, ^a   Boggess, John F ^a   Gehrig, Paola A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Arsenic; Endometrial cancer; Estrogen receptor; MAPK pathway

Indexed keywords

ARSENIC TRIOXIDE; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UO 126; ORGANOARSENIC DERIVATIVE; OXIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; ENDOMETRIUM CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ARSENICALS; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDES;

EID: 57849157448     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719108324134     Document Type: Article

References (31)

1. Miller, WH Jr, Schipper HM, Lee JS, Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002 ; 62: 3893-3903.
2. Evens AM, Tallman MS, Gartenhaus RB The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res. 2004 ; 28: 891-900.
3. Gazitt Y., Akay C. Arsenic trioxide: an anti cancer missile with multiple warheads. Hematology. 2005 ; 10: 205-213.
4. Soignet SL, Maslak P., Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998 ; 339: 1341-1348.
5. Soignet SL, Frankel SR, Douer D., et al. United States multi-center study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001 ; 19: 3852-3860.
6. Murgo AJ Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist. 2001 ; 6 (suppl 2). 22-28.
7. Murgo AJ, McBee WL, Cheson BD Clinical trials referral resource. Clinical trials with arsenic trioxide. Oncology (Williston Park). 2000 ; 14: 206, 211, 215-216 passim.
8. Han B., Zhou G., Zhang Q., et al. Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp. J Exp Ther Oncol. 2004 ; 4: 335-342.
9. Chow SK, Chan JY, Fung KP Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J Cell Biochem. 2004 ; 93: 173-187.
10. Li X., Ding X., Adrian TE Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest. 2004 ; 22: 389-400.
11. Um SJ, Lee SY, Kim EJ, Myoung J., Namkoong SE, Park JS Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells. Cancer Lett. 2002 ; 181: 11-22.
12. Kong B., Huang S., Wang W., et al. Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines. Int J Gynecol Cancer. 2005 ; 15: 872-877.
13. Bornstein J., Sagi S., Haj A., Harroch J., Fares F. Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line. Gynecol Oncol. 2005 ; 99: 726-729.
14. Shen ZY, Shen J., Chen MH, Wu XY, Wu MH, Zeng Y. The inhibition of growth and angiogenesis in heterotransplanted esophageal carcinoma via intratumoral injection of arsenic trioxide. Oncol Rep. 2003 ; 10: 1869-1874.
15. Lin LM, Li BX, Xiao JB, Lin DH, Yang BF Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro. World J Gastroenterol. 2005 ; 11: 5633-5637.
16. Uslu R., Sanli UA, Sezgin C., et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res. 2000 ; 6: 4957-4964.
17. Zhang J., Wang B. Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. Gynecol Oncol. 2006 ; 103: 199-206.
18. Dilda PJ, Hogg PJ Arsenical-based cancer drugs. Cancer Treat Rev. 2007 ; 33: 542-564.
19. Chow SK, Chan JY, Fung KP Suppression of cell proliferation and regulation of estrogen receptor alpha signaling pathway by arsenic trioxide on human breast cancer MCF-7 cells. J Endocrinol. 2004 ; 182: 325-337.
20. Chen GC, Guan LS, Hu WL, Wang ZY Functional repression of estrogen receptor a by arsenic trioxide in human breast cancer cells. Anticancer Res. 2002 ; 22: 633-638.
21. Stoica A., Pentecost E., Martin MB Effects of arsenite on estrogen receptor-alpha expression and activity in MCF-7 breast cancer cells. Endocrinology. 2000 ; 141: 3595-3602.
22. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun MJ Cancer statistics, 2007. CA Cancer J Clin. 2007 ; 57: 43-66.
23. Abal M., Planaguma J., Gil-Moreno A., et al. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors. Histol Histopathol. 2006 ; 21: 197-204.
24. Hecht JL, Mutter GL Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006 ; 24: 4783-4791.
25. Lax SF Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004 ; 444: 213-223.
26. Zhou C., Boggess JF, Bae-Jump V., Gehrig PA Induction of apoptosis and inhibition of telomerase activity by arsenic trioxide (As2O3) in endometrial carcinoma cells. Gynecol Oncol. 2007 ; 105: 218-222.
27. Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol. 2002 ; 62: 529-538.
28. Davey JC, Bodwell JE, Gosse JA, Hamilton JW Arsenic as an endocrine disruptor: effects of arsenic on estrogen receptor-mediated gene expression in vivo and in cell culture. Toxicol Sci. 2007 ; 98: 75-86.
29. Ye J., Li A., Liu Q., Wang X., Zhou J. Inhibition of mitogen-activated protein kinase kinase enhances apoptosis induced by arsenic trioxide in human breast cancer MCF-7 cells. Clin Exp Pharmacol Physiol. 2005 ; 32: 1042-1048.
30. Lunghi P., Tabilio A., Lo- Coco F., Pelicci PG, Bonati A. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia. 2005 ; 19: 234-244.
31. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002 ; 298: 1911-1912.